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From the University Department of Chemical Pathology, Royal Infirmary, Sheffield SYNOPSIS Serum folic acid levels and the urinary excretion of Figlu have been studied in patients with leukaemia or lymphomas. The results indicate that folic acid deficiency is a common complication of these diseases. Bone marrow examinations of those with evidence of such a deficiency frequently show megaloblastic erythropoiesis.
The Figlu test appears to be a useful screening test for folic acid deficiency in patients with leukaemia or lymphomas.
Evidence that folic acid deficiency may develop in patients suffering from leukaemia or lymphomas has been obtained from studies of the excretion of folic acid in urine (Swendseid, Swanson, Meyers, and Bethell, 1952; Girdwood, 1953) , of the rate of clearance of injected folic acid from the plasma (Hogan, Maniatis, and Moloney, 1964) , and from serum folic acid assays (Hoogstraten, Baker, and Reizen-stein, 1961; Rao, Lagerlof, Einhorn, and Reizen-stein, 1963 ; Kershaw and Girdwood, 1964) .
The number of patients studied by previous authors has been too small to indicate the frequency with which folic acid deficiency is a complicating factor in the various forms of leukaemia and lymphomas. In the present study groups of patients with acute leukaemia, chronic lymphocytic leukaemia, lymphosarcoma, reticulum cell sarcoma, and Hodgkin's disease have been investigated for evidence of folic acid deficiency. In addition to serum folic acid estimations and bone marrow examinations, the excretions of formiminoglutamic acid (Figlu) in urine have been estimated. Increased excretions of Figlu have been reported in malignant diseases (Dymock, 1964) , but the significance of these observations remains to be established.
MATERIAL AND METHODS
The composition of the patients studied is given in Tables I (acute leukaemia) and 1I (chronic lymphocytic leukaemia and lymphomas). The cases of acute leukaemia were investigated before starting treatment.
The haematological estimations were performed by standard methods, the fasting serum folic acid assays by the Lactobacillus casei method (normal range 5 to 22 m,ug. per ml.), and the serum vitamin B12 assays by the Euglena gracilis technique (normal range 140 to 850 uug. per ml.). Case 29 (reticulum cell sarcoma) showed a sudden fall in the haemoglobin level which was accompanied by the appearance of macrocytes in the peripheral blood and megaloblasts in the bone marrow. Intestinal malabsorption was indicated by a faecal fat excretion of 8-1 g. per day (average result for a four-day period; normal less than 6 g. daily) and impaired xylose absorption (1-3 g. xylose excreted in five hours following a 25 g. oral dose of xylose; lower limit of the normal range 4-0 g. 6-5 6-9 9.4 6-4 5.9 6-9 8-3 8-5 7 0 30,000 73,000 2,000 35,000 7,000 28,000 1,800 77,000 12,000 Case 40 (Hodgkin's disease) also presented with a rapidly developing megaloblastic anaemia. The results of the serum folic acid assay and the Figlu test were consistent with folic acid deficiency and he was treated with folic acid, 15 mg. daily. Within one month the haemoglobin level had risen from 6-0 to 10-2 g. per 100 ml. and three months later it was 15-2 g./ml. The Figlu excretion test became normal and the macrocytes disappeared from the peripheral blood.
Case 38 (Hodgkin's disease) had suffered from a microcytic anaemia, requiring blood transfusions, for several months. At the time of investigation, however, he had developed a severe glossitis and macrocytes were present in the peripheral blood. A bone marrow examination showed megaloblastic erythropoiesis and there was evidence of folic acid deficiency. The glossitis improved rapidly with folic acid therapy. There was, however, no improvement in the haemoglobin level, the haematological features being again those of a microcytic, normochromic anaemia.
DISCUSSION
The cause of folic acid deficiency in leukaemia and lymphomas has not been established with certainty. Leukaemia cells have a higher folic acid content than normal leucocytes (Swendseid, Bethell, and Bird, 1951) suggesting that one factor may be an abnormal demand for folic acid derivatives. Impaired intestinal absorption may also play a part in chronic lymphocytic leukaemia and lymphomas (Pitney, Joske, and Mackinnon, 1960 , and case 29 in the present series).
Previous workers have reported low serum folic acid levels in leukaemias and lymphomas. Rao et al. (1963) The clinical significance of folic acid deficiency in leukaemia and lymphomas remains to be elucidated. The administration of folic acid to patients with acute leukaemia may accelerate the progress of the disease (Farber, Diamond, Mercer, Sylvester, and Wolff, 1948) . The responses of the three patients with lymphomas (cases 29, 38, and 40 in the present series) suggest that folic acid therapy may have a place in the management of these diseases when there is evidence of folate deficiency.
The results of the Figlu tests agreed well, on the whole, with the serum folic acid levels. There were, however, six patients with increased Figlu excretions but normal serum folic acid results. These may have resulted from malignant infiltration of the liver with impairment of the enzymes concerned in histidine metabolism. One of the six patients (case 37) had abnormal liver function tests.
